黄连-厚朴不同配伍比例对抑制大鼠神经氨酸酶活性影响
|
摘要
目的:研究黄连-厚朴药不同配伍比例对抑制神经氨酸酶活性的影响。方法:选取无特定病原体级SD大鼠120只为研究对象,将其平均分为12组,每组10只鼠,一组作为空白对照组,一组为奥司他韦组,一组为模型对照组,其余9组为不同配伍组。观察记录大鼠的体重、身长等一般病理特征,记录抑制率和拮抗剂的半抑制浓度,并记录三维响应面模型表示结果(黄连-厚朴协同、相加和拮抗作用情况以及协同作用最优时的配伍比例)。结果:黄连-厚朴不同配伍比例对神经氨酸酶活性影响差异较大,配伍比例为1:1时,对神经氨酸酶抑制率最高,拮抗剂的半抑制浓度最低;黄连-厚朴不同配伍比例药物之间作用主要是相加,然后是协同,拮抗作用最弱,当黄连和厚朴配伍比例在0.55∶1～1.11∶1范围内时,两种药物协同作用最为显著,协同作用强度达到-0.800,其他配伍比例呈现较强的拮抗或者相加作用。结论:黄连-厚朴药不同配伍比例对抑制神经氨酸酶活性的影响效果不同,最优配伍比例为1∶1。
Objective:To study the effect of different proportions of Rhizoma Coptidis-Magnolia Chinese herb on the inhibition of neuraminidase activity.Methods:120 non-special pathogenic SD rats were selected as study subjects and divided into 12 groups with 10 rats in each group.One group served as blank controlled group,one group was oseltamivir group,and one group was model controlled.Group,the remaining 9 groups were different compatibility groups.Observing and recording the general pathological features such as body weight and body length of the rats,recording the inhibition rate and the half inhibitory concentration of the antagonist,and recording the results of the three-dimensional response surface model:the synergistic,additive and antagonistic effects of Coptis chinensis and Magnolia officinalis and the optimal synergy.The proportion of compatibility.Results:The ratio of different combinations of Rhizoma Coptidis-Homoppain to neuraminidase had a great influence on neuraminidase activity.The ratio of neuraminidase was the highest and the semi-inhibitory concentration of antagonist was the lowest when the compatibility ratio was 1:1.The main effects of drugs were additive,followed by synergy,and the weakest antagonistic effect.When the proportion of Coptidis Rhizoma and Magnolia officinale was in the range of 0.55:1 to 1.11:1,the synergistic effect of the two drugs was most significant,and the synergistic effect reached at-0.800,other compatibility ratios showed strong antagonism or additive effects.Conclusion:The effects of different combinations of Coptidis Rhizoma-Magnolia officinalis on inhibition of neuraminidase activity were different,and the optimal compatibility ratio was 1:1.
Objective:To study the effect of different proportions of Rhizoma Coptidis-Magnolia Chinese herb on the inhibition of neuraminidase activity.Methods:120 non-special pathogenic SD rats were selected as study subjects and divided into 12 groups with 10 rats in each group.One group served as blank controlled group,one group was oseltamivir group,and one group was model controlled.Group,the remaining 9 groups were different compatibility groups.Observing and recording the general pathological features such as body weight and body length of the rats,recording the inhibition rate and the half inhibitory concentration of the antagonist,and recording the results of the three-dimensional response surface model:the synergistic,additive and antagonistic effects of Coptis chinensis and Magnolia officinalis and the optimal synergy.The proportion of compatibility.Results:The ratio of different combinations of Rhizoma Coptidis-Homoppain to neuraminidase had a great influence on neuraminidase activity.The ratio of neuraminidase was the highest and the semi-inhibitory concentration of antagonist was the lowest when the compatibility ratio was 1:1.The main effects of drugs were additive,followed by synergy,and the weakest antagonistic effect.When the proportion of Coptidis Rhizoma and Magnolia officinale was in the range of 0.55:1 to 1.11:1,the synergistic effect of the two drugs was most significant,and the synergistic effect reached at-0.800,other compatibility ratios showed strong antagonism or additive effects.Conclusion:The effects of different combinations of Coptidis Rhizoma-Magnolia officinalis on inhibition of neuraminidase activity were different,and the optimal compatibility ratio was 1:1.
引文
[1]Yaeghoobi M,Frimayanti N,Chee C F,et al.QSAR,in silico docking and in vitro evaluation of chalcone derivatives as potential inhibitors for H1N1 virus neuraminidase[J].Medicinal Chemistry Research,2016,25(10):1~10
[2]李在建,王旭,龙良启,等.副猪嗜血杆菌神经氨酸酶序列分析及可溶性表达[J].江苏农业科学,2018,46(6):40~42
[3]Lee I K,Hwang B S,Kim D W,et al.Characterization of Neuraminidase Inhibitors in Korean Papaver rhoeas Bee Pollen Contributing to Anti-Influenza Activities In Vitro[J].Planta Medica,2016,82(06):524~529
[4]曹雨,李金花,刘海波,等.隔山消抗神经氨酸酶活性及化学成分研究[J].中草药,2017,48(21):4485~4492
[5]于悦洋,谢怡然,陈迎珠,等.抗H7N9亚型流感病毒神经氨酸酶单克隆抗体的制备及初步鉴定[J].中华实验和临床病毒学杂志,2017,31(1):66~70
[6]刘青杰,陆雪,陈德清,等.《荧光原位杂交分析染色体易位估算辐射生物剂量技术方法》解读[J].国际放射医学核医学杂志,2012,36(4):245~248
[7]Hossain M A,Higaki K,Shinpo M,et al.Chemical chaperone treatment for galactosialidosis:Effect of NOEV onβ-galactosidase activities in fibroblasts[J].Brain&Development,2016,38(2):175~180
[8]M?gling R,Richard M J,Vliet S V,et al.Neuraminidasemediated haemagglutination of recent human influenza A(H3N2)viruses is determined by arginine 150 flanking the neuraminidase catalytic site[J].Journal of General Virology,2017,98(6):1274~1281
[9]卢元赫,张玲玲,张,等.牛副流感病毒3型血凝素-神经氨酸酶蛋白在杆状病毒中的表达[J].中国生物制品学杂志,2016,29(4):360~364
[10]Zhang M,Zhao H,Zhao Z,et al.Rapid screening,identification and purification of neuraminidase inhibitors from Lithospermum erythrorhizon Sieb.et Zucc.by ultrafiltration with HPLC-ESI-TOF-MS combined with semi-preparative HPLC[J].Journal of Separation Science,2016,39(11):2097~2104
[11]池絮影,傅咏梅,崔曰新,等.板蓝根化学成分与抗流感病毒神经氨酸酶活性相关性的探讨[J].中草药,2016,47(22):3982~3989
[12]Durrant J D,Bush R M,Amaro R E.Microsecond Molecular Dynamics Simulations of Influenza Neuraminidase Suggest a Mechanism for the Increased Virulence of Stalk-Deletion Mutants[J].Journal of Physical Chemistry B,2016,120(33):8590~8599
[13]葛资宇,童骄,那婧婧,等.不同煎煮方法的麻杏石甘汤及其含药血清对A型流感病毒神经氨酸酶活性的影响[J].中国中西医结合杂志,2016,36(9):1119~1123
[14]张伟强,郭豫杰,李赛赛,等.新城疫病毒血凝素-神经氨酸酶蛋白的可溶性超表达与免疫活性检测[J].解剖学报,2016,47(6):848~855
[15]Gamaleldin E K M,Matei M F,Jaiswal R,et al.Neuraminidase inhibition of Dietary chlorogenic acids and derivatives-potential antivirals from dietary sources[J].Food Function,2016,7(4):2052~2059
[16]徐康维,顾琴,邵铭,等.甲型H1N1流感疫苗中神经氨酸酶含量双抗体夹心ELISA检测方法的建立与应用[J].微生物学免疫学进展,2016,44(6):1~4
[17]Sriwilaijaroen N,Magesh S,Imamura A,et al.A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases:Insight into Neuraminidase-Inhibitor Interactions[J].Journal of Medicinal Chemistry,2016,59(10):4563~4577
[18]杨巧利,郭菁菁,代斌玲,等.槲寄生内生菌IA-4~2及其代谢产物的分离、鉴定和神经氨酸酶抑制作用考察[J].中国药师,2016,19(8):1442~1445
[19]Chen Y Q,Wohlbold T J,Zheng N Y,et al.Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies.[J].Cell,2018,173(4):417~429
[20]王敬,刘盼和,袁建勇,等.一种新型苯甲酸衍生物类神经氨酸酶抑制剂的合成及体外酶抑制活性[J].中国医药工业杂志,2017,48(8):1119~1124
[21]Lee C Y,Kwon H J,Nguyen T T,et al.Effect of the fourth nucleotide at the 3'end of neuraminidase and matrix viral genomic RNA on the pathogenicity of influenza virus A/PR/8/34.[J].Journal of Veterinary Science,2017,18(1):307~313
[22]简瑶.基于化学荧光法的双黄连口服液神经氨酸酶抑制活性测定[J].成都大学学报(自然科学版),2017,36(1):21~23
[2]李在建,王旭,龙良启,等.副猪嗜血杆菌神经氨酸酶序列分析及可溶性表达[J].江苏农业科学,2018,46(6):40~42
[3]Lee I K,Hwang B S,Kim D W,et al.Characterization of Neuraminidase Inhibitors in Korean Papaver rhoeas Bee Pollen Contributing to Anti-Influenza Activities In Vitro[J].Planta Medica,2016,82(06):524~529
[4]曹雨,李金花,刘海波,等.隔山消抗神经氨酸酶活性及化学成分研究[J].中草药,2017,48(21):4485~4492
[5]于悦洋,谢怡然,陈迎珠,等.抗H7N9亚型流感病毒神经氨酸酶单克隆抗体的制备及初步鉴定[J].中华实验和临床病毒学杂志,2017,31(1):66~70
[6]刘青杰,陆雪,陈德清,等.《荧光原位杂交分析染色体易位估算辐射生物剂量技术方法》解读[J].国际放射医学核医学杂志,2012,36(4):245~248
[7]Hossain M A,Higaki K,Shinpo M,et al.Chemical chaperone treatment for galactosialidosis:Effect of NOEV onβ-galactosidase activities in fibroblasts[J].Brain&Development,2016,38(2):175~180
[8]M?gling R,Richard M J,Vliet S V,et al.Neuraminidasemediated haemagglutination of recent human influenza A(H3N2)viruses is determined by arginine 150 flanking the neuraminidase catalytic site[J].Journal of General Virology,2017,98(6):1274~1281
[9]卢元赫,张玲玲,张,等.牛副流感病毒3型血凝素-神经氨酸酶蛋白在杆状病毒中的表达[J].中国生物制品学杂志,2016,29(4):360~364
[10]Zhang M,Zhao H,Zhao Z,et al.Rapid screening,identification and purification of neuraminidase inhibitors from Lithospermum erythrorhizon Sieb.et Zucc.by ultrafiltration with HPLC-ESI-TOF-MS combined with semi-preparative HPLC[J].Journal of Separation Science,2016,39(11):2097~2104
[11]池絮影,傅咏梅,崔曰新,等.板蓝根化学成分与抗流感病毒神经氨酸酶活性相关性的探讨[J].中草药,2016,47(22):3982~3989
[12]Durrant J D,Bush R M,Amaro R E.Microsecond Molecular Dynamics Simulations of Influenza Neuraminidase Suggest a Mechanism for the Increased Virulence of Stalk-Deletion Mutants[J].Journal of Physical Chemistry B,2016,120(33):8590~8599
[13]葛资宇,童骄,那婧婧,等.不同煎煮方法的麻杏石甘汤及其含药血清对A型流感病毒神经氨酸酶活性的影响[J].中国中西医结合杂志,2016,36(9):1119~1123
[14]张伟强,郭豫杰,李赛赛,等.新城疫病毒血凝素-神经氨酸酶蛋白的可溶性超表达与免疫活性检测[J].解剖学报,2016,47(6):848~855
[15]Gamaleldin E K M,Matei M F,Jaiswal R,et al.Neuraminidase inhibition of Dietary chlorogenic acids and derivatives-potential antivirals from dietary sources[J].Food Function,2016,7(4):2052~2059
[16]徐康维,顾琴,邵铭,等.甲型H1N1流感疫苗中神经氨酸酶含量双抗体夹心ELISA检测方法的建立与应用[J].微生物学免疫学进展,2016,44(6):1~4
[17]Sriwilaijaroen N,Magesh S,Imamura A,et al.A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases:Insight into Neuraminidase-Inhibitor Interactions[J].Journal of Medicinal Chemistry,2016,59(10):4563~4577
[18]杨巧利,郭菁菁,代斌玲,等.槲寄生内生菌IA-4~2及其代谢产物的分离、鉴定和神经氨酸酶抑制作用考察[J].中国药师,2016,19(8):1442~1445
[19]Chen Y Q,Wohlbold T J,Zheng N Y,et al.Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies.[J].Cell,2018,173(4):417~429
[20]王敬,刘盼和,袁建勇,等.一种新型苯甲酸衍生物类神经氨酸酶抑制剂的合成及体外酶抑制活性[J].中国医药工业杂志,2017,48(8):1119~1124
[21]Lee C Y,Kwon H J,Nguyen T T,et al.Effect of the fourth nucleotide at the 3'end of neuraminidase and matrix viral genomic RNA on the pathogenicity of influenza virus A/PR/8/34.[J].Journal of Veterinary Science,2017,18(1):307~313
[22]简瑶.基于化学荧光法的双黄连口服液神经氨酸酶抑制活性测定[J].成都大学学报(自然科学版),2017,36(1):21~23